Evidence map›Paper›PMID 27008550›Full record

ArticlePloS one2016

A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine Candidates.

Dhanasekaran Govindarajan, Liming Guan, Steven Meschino, Arthur Fridman, Ansu Bagchi, Irene Pak, Jan ter Meulen, Danilo R Casimiro, Andrew J Bett

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Designing a polytope for use in a broad-spectrum dengue virus vaccine.Journal of Taibah University Medical Sciences · 2018
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dhanasekaran GovindarajanMerck Research Laboratories, Merck & Co., Kenilworth, NJ, United States of America.
Liming GuanMerck Research Laboratories, Merck & Co., Kenilworth, NJ, United States of America.
Steven MeschinoMerck Research Laboratories, Merck & Co., Kenilworth, NJ, United States of America.
Arthur FridmanMerck Research Laboratories, Merck & Co., Kenilworth, NJ, United States of America.
Ansu BagchiMerck Research Laboratories, Merck & Co., Kenilworth, NJ, United States of America.
Irene PakMerck Research Laboratories, Merck & Co., Kenilworth, NJ, United States of America.
Jan ter MeulenImmune Design Corporation, Seattle, WA, United States of America.
Danilo R CasimiroMerck Research Laboratories, Merck & Co., Kenilworth, NJ, United States of America.
Andrew J BettMerck Research Laboratories, Merck & Co., Kenilworth, NJ, United States of America.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USMetis Design Corporation (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue is one of the most important mosquito-borne infections accounting for severe morbidity and mortality worldwide. Recently, the tetravalent chimeric live attenuated Dengue vaccine Dengvaxia® was approved for use in several dengue endemic countries. In general, live attenuated vaccines (LAV) are very efficacious and offer long-lasting immunity against virus-induced disease. Rationally designed LAVs can be generated through reverse genetics technology, a method of generating infectious recombinant viruses from full length cDNA contained in bacterial plasmids. In vitro transcribed (IVT) viral RNA from these infectious clones is transfected into susceptible cells to generate recombinant virus. However, the generation of full-length dengue virus cDNA clones can be difficult due to the genetic instability of viral sequences in bacterial plasmids. To circumvent the need for a single plasmid containing a full length cDNA, in vitro ligation of two or three cDNA fragments contained in separate plasmids can be used to generate a full-length dengue viral cDNA template. However, in vitro ligation of multiple fragments often yields low quality template for IVT reactions, resulting in inconsistent low yield RNA. These technical difficulties make recombinant virus recovery less efficient. In this study, we describe a simple, rapid and efficient method of using LONG-PCR to recover recombinant chimeric Yellow fever dengue (CYD) viruses as potential dengue vaccine candidates. Using this method, we were able to efficiently generate several viable recombinant viruses without introducing any artificial mutations into the viral genomes. We believe that the techniques reported here will enable rapid and efficient recovery of recombinant flaviviruses for evaluation as vaccine candidates and, be applicable to the recovery of other RNA viruses.

Indexed as

AnimalsChlorocebus aethiopsDengueDengue VaccinesDengue VirusFemaleMacaca mulattaMaleNeutralization TestsPolymerase Chain ReactionRecombinant Fusion ProteinsVaccines, DNAVero CellsYellow fever virusDengue VaccinesRecombinant Fusion ProteinsVaccines, DNA

Identifiers

PMID27008550
PMCPMC4805244
OpenAlexW2306949113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.